Naperville, IL -- (SBWIRE) -- 10/29/2013 -- Reportstack, provider of premium market research reports announces the addition of Crenezumab (Alzheimers Disease) - Forecast and Market Analysis to 2022 market report to its offering
Crenezumab (Alzheimers Disease) - Forecast and Market Analysis to 2022
The publisher has released its new PharmaPoint Drug Evaluation report, Crenezumab (Alzheimers Disease) - Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimers Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Crenezumab is a humanized IgG4 mAb in development for passive immunization therapy for AD. Crenezumab works by binding to both monomeric and oligomeric forms of A, thereby preventing its aggregation, while also promoting plaque disaggregation. It can be administered subcutaneously or intravenously.
- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Crenezumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Crenezumab for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Crenezumab performance
- Obtain sales forecast for Crenezumab from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
To view the table of contents for this market research report please visit